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Abstract
Background: Autophagy is a bulk degradation pathway for long-lived proteins, protein aggregates, and damaged
organelles. ULK1 protein kinase and Vps34 lipid kinase are two key autophagy regulators that are critical for
autophagosome biogenesis. However, it isn’t fully understood how ULK1 regulates Vps34, especially in the context
of disease. Polyglutamine expansion in huntingtin (Htt) causes aberrant accumulation of the aggregated protein
and disrupts various cellular pathways including autophagy, a lysosomal degradation pathway, underlying the
pathogenesis of Huntington’s disease (HD). Although autophagic clearance of Htt aggregates is under investigation
as therapeutic strategy for HD, the precise mechanism of autophagy impairment remains poorly understood.
Moreover, in-vivo assays of autophagy have been particularly challenging due to lack of reliable and robust
molecular biomarkers.
Method: We generated anti-phosphorylated ATG14 antibody to determine ATG14-mediated autophagy regulation;
we employed Huntington’s disease (HD) genetic cell models and animal models as well as autophagy reporter
animal model to understand autophagy signaling and regulation in vivo. We applied biochemical analysis and
molecular biology approaches to dissect the alteration of autophagy kinase activity and regulation.
Results: Here, we demonstrate that ULK1 phosphorylates ATG14 at serine 29 in an mTOR-dependent manner.
This phosphorylation critically regulates ATG14-Vps34 lipid kinase activity to control autophagy level. We also show
that ATG14-associated Vps34 activity and ULK1-mediated phosphorylation of ATG14 and Beclin 1 are compromised
in the Q175 mouse model of Huntington’s disease. Finally, we show that ATG14 phosphorylation is decreased
during general proteotoxic stress caused by proteasomal inhibition. This reduction of the specific phosphorylation
of ATG14 and Beclin 1 is mediated, in part, by p62-induced sequestration of ULK1 to an insoluble cellular
fraction. We show that increased ULK1 levels and phosphor-mimetic mutant ATG14 facilitate the clearance
of polyQ mutant in cells.
Conclusion: Our study identifies a new regulatory mechanism for ATG14-Vps34 kinase activity by ULK1, which
can be used as valuable molecular markers for in-vivo autophagic activity as well as potential therapeutic
target for the clearance of polyglutamine disease protein.
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Background
Macroautophagy (simply referred to as autophagy) is a
lysosome degradation pathway involving the synthesis,
trafficking, and degradation of autophagic vacuoles, or
autophagosomes. Basal autophagy is responsible for the
turnover of long-lived proteins, protein aggregates, and
damaged organelles, but can also be upregulated to cope
with various cellular stressors. In fact, autophagy disre-
gulation has been implicated in many disease states.
Several studies of postmortem Huntington’s disease
(HD) brains and animal models have indicated altered
autophagic activity [1–4]. As a bulk cellular degradation
pathway, autophagy has also been extensively studied for
its neuroprotective potential through the removal of
mutant huntingtin (Htt) [5]. However, the precise path-
ways involved in autophagy during Huntington’s disease
(HD) are still being clarified.
Autophagy is tightly regulated by multiple signaling
pathways related to nutrient sensing and cellular stress.
ULK1 is a serine/threonine kinase that initiates the
autophagy cascade [6]. ULK1 is regulated in part by
mTOR and AMPK, which inhibit and activate ULK1, re-
spectively [7]. Immediately downstream of ULK1 is the
class III PI 3-kinase, Vps34. Vps34 phosphorylates phos-
phatidylinositol at the 3′ position to form PI(3)P [8],
which serves as a second messenger to facilitate the re-
cruitment of later stage, autophagy-related proteins to
the site of autophagosome formation. However, Vps34
activity is not limited to autophagy; it is also involved in
endosomal sorting and cytokinesis [9, 10]. Vps34 exists
in multiple distinct complexes with Beclin 1 and VPS15
[11], but Vps34 in complex with ATG14 is exclusive to
autophagy initiation. Upon autophagy induction, ATG14-
Vps34 is recruited to the site of autophagosome biogenesis
in an ULK1-dependent manner [12].
HD is a fatal neurodegenerative disease caused by
mutations in the Htt gene that code for expanded poly-
glutamine tracts (polyQ) in the first exon, which causes
protein aggregation and neuronal loss throughout the
brain, most notably in the striatum and cortex. The
precise nature of autophagy alterations in HD is not
completely understood. However, increasing autophagy
has been shown to facilitate the clearance of mutant Htt
aggregates [1, 13]. Therefore, understanding the status
of autophagy in the context of HD is crucial for the
rational design of autophagy-based therapeutics.
Recent work has aimed at understanding the autoph-
agy pathway in finer detail, during the HD pathogenesis.
As part of this, a link between the ULK1 kinase and the
autophagy receptor, p62/SQSTM1, has been identified.
ULK1 phosphorylates p62 to promote selective autoph-
agy in response to proteotoxic stress [14]. Expression of
mutant Htt causes an increase in p62 phosphorylation,
which can also facilitate autophagic clearance of polyQ
protein. Unexpectedly, loss of p62 actually alleviates
toxicity in HD mouse models, pointing to a negative
impact of p62 in the disease progression [15]. However,
it is not fully understood how ULK1 regulates autoph-
agy, especially in the context of protein aggregate prone
neurodegenerative diseases.
Herein, we report a mechanism whereby ATG14-
Vps34 activity is regulated by ULK1-mediated phosphor-
ylation of ATG14. This phosphorylation occurs in an
mTOR-dependent fashion. In contrast to our previous
report of increased ULK1-mediated p62 phosphorylation
in animal and cellular HD models [14], we show that
ATG14 phosphorylation and ATG14-Vps34 activity is
decreased in Q175 mice. Furthermore, decreased
ATG14 phosphorylation is observed during general
proteotoxic stress, which we propose is caused by
recruitment of ULK1 away from ATG14 by p62.
Methods
Antibodies and reagents
Vps34 (#4263), Myc (#2276), Actin (#3700), and Beclin 1
pS14 (#84966) were purchased from Cell Signaling
Technologies (Danvers, MA). Vps15 (#A302-571A), and
NRBF2 (#A301-852A) were purchased from Bethyl
Laboratories. ATG14 (MBL; #PD026), polyQ (Merck
Millipore; #MAB1574), huntingtin aggregates (Merck
Millipore, #MAB5374) Beclin 1 (Santa Cruz Biotechnol-
ogy; #sc-11427), LC3 (Abcam; #ab48394), Flag-M2
(Sigma-Aldrich; #F1804), p62 (American Research Prod-
ucts; #03-GP62-C), p62 pS409 (in house), ULK1 (Sigma-
Aldrich, #A7481), GAPDH (Thermofisher; #2D4A7),
and GFP (Roche; #11814460001) were purchased from
indicated company. The ATG14 antibody used to detect
the purified fragment (a.a. 20–73) was made in house [11].
Anti–phosphorylated ATG14 polyclonal antibody was
raised in rabbits using the peptide RDLVD(pS)VDDAEGC
as an antigen by Cocalico Biologicals. MG132 (Calbio-
chem), isopropyl-β-D-thiogalactopyranoside (IPTG; Sigma-
Aldrich), lipofectamine 2000 (Invitrogen), EDTA-free
protease inhibitor cocktail and phosphatase inhibitor
cocktail (Roche Diagnostics), Dynabeads protein G (Invi-
trogen), NuPAGE Bis-Tris gel system (Invitrogen), Quik-
Change Lightning Site-Directed Mutagenesis Kit (Agilent
Technologies), Hybond-P PVDF membrane (GE Health-
care Life Sciences), BCA Protein Assay Reagent Kit
(Pierce), Radioactive [γ-32P]ATP (PerkinElmer), Calf
intestinal alkaline phosphatase (New England Biolabs),
and TALON metal affinity resin (Clontech) were pur-
chased from the companies listed.
Plasmids
Myc-ULK1 wildtype and kinase inhibited (K46I) mutant
were provided by Dr. Sharon Tooze (London Research
Institute). Beclin 1-AsRed, ATG14-GFP, FLAG-ATG14,
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and myc-Vps34-his-Vps15 plasmids were generated as
previously described [11]. ATG14 a.a. 20–73 was pro-
vided as a generous gift by Dr. Yanxiang Zhao (Hong
Kong Polytechnic University).
Cell culture
MEF, HEK293T, HCT116, and HeLa cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen) and 50 μg/mL penicillin and streptomycin
(Invitrogen). Wild type and p62 KO MEF cells were
provided by Dr. Masaaki Komatsu (Niigata University)
[16]. ATG14 KO HCT cells were generously provided by
Dr. Richard Youle (National Institute of Neurological
Disorders and Stroke) [17] and were maintained in
McCoy’s 5A plus media (Invitrogen) supplemented with
10% fetal bovine serum, 1X non-essential amino acids
(Invitrogen), and glutamine (4 mM final concentration).
PolyQ-mCFP HeLa cells were maintained as previously
described [13], which were generous gifts from Dr. Ai
Yamamoto (Columbia University). Wildtype and ULK1/2
double KO MEFs were a provided by Dr. Mondira
Kundu (St. Jude Children’s Research Hospital). Transient
DNA transfection of HEK293T and HeLa cells was
performed using Lipofectamine 2000 kit according to
the manufacturer’s manual (Invitrogen).
Immunoblot analysis
All IP’s were performed using 10 mM Tris–HCl pH 7.5,
2 mM EDTA, 100 mM NaCl, 1% NP-40, protease inhibi-
tor cocktail (Roche) and phosphatase inhibitor cocktail
(Roche). All other lysates were prepared using 50 mM
Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate, 1 mM EDTA, an protease/phosphatase
inhibitors (Roche). Supernatants were collected after
centrifugation at 13,000 g for 15 min at 4 °C. Superna-
tants were subjected to BCA assay and then resolved by
SDS-PAGE.
In vitro lipid kinase assays
Immunoprecipitation was performed with 500 μg pro-
tein from post-nuclear supernatant, using antibodies
against ATG14 (MBL) overnight at 4 °C. Samples were
incubated with 30 μl Dynabeads (Life Technologies) for
1– 2 h at 4 °C and then washed three times with lysis
buffer. Two thirds of the beads were reserved for west-
ern blotting, while the remaining third was used for the
kinase assay. Beads for the kinase assay were washed
once with wash buffer (20 mM HEPES pH 7.4, 1 mM
EGTA, 0.4 mM EDTA, 5 mM MgCl2, and 0.05 mM
DTT) and then resuspended to a final volume of 50 μl
with reaction buffer (20 mM HEPES pH 7.4, 1 mM
EGTA, 0.4 mM EDTA, 5 mM MgCl2, and 0.05 mM
DTT, 50 mM cold ATP, 5 mM MnCl2, 0.1 mg/ml
sonicated phosphatidylinositol). 10 nM wortmannin was
included in the indicated controls. The reaction was
started with the addition of γ-32P-ATP (5 mCi) and the
samples were shaken at 37 °C for 30 min. Reactions were
stopped with 120 μl stop buffer (CHCl3/CH3OH/HCl at
a 10:20:0.2 volume ratio) and then shaken for another
10 min at room temperature. Samples were centrifuged
for 5 min at 1000 g. 15 μl of the lower, organic phase was
resolved on silica coated TLC plate (Millipore) using
CHCl3/CH3OH/NH4OH/H2O (86:76:10:14 volume ratio)
and visualized with the Typhoon 9400 Variable Imager
(GE Healthcare Biosciences).
In vitro ULK1 kinase assay
Myc-ULK1 WT, myc-ULK1 kinase inhibited, or myc pro-
tein was immunopurified from HEK cells using anti-myc
antibodies. IPs were washed once with kinase buffer
(20 mM HEPES pH 7.4, 12.5 mM beta-glycerophosphate,
25 mMMgCl2, 5 mM EGTA, 0.25 mM DTT, 100 μM cold
ATP, protease inhibitor cocktail (Roche) and phosphatase
inhibitor cocktail (Roche)) and then resuspended to a final
volume of 50 μl with reaction buffer including 5 μg of
substrate (ATG14 a.a. 20–73 or MBP) and 5 μCi 32P-ATP.
Reaction was incubated at 37 °C for 30 min. Samples were
subject to gel electrophoresis in a 4–12% bis-tris gel. The
gel was visualized with the Typhoon 9400 Variable Imager
(GE Healthcare Biosciences).
Protein expression and purification
Expression of His-ATG14 a.a. 20–73 was induced in E.coli
BL21-CodonPlus (Agilent) cells by growing at room
temperature for 16 h with 0.05 mM of IPTG. Bacterial cell
lysis and protein purification was done using the TALON
metal affinity resin kit in strict accordance with the
recommended manufacturers protocol (Clontech).
Triton X-100 soluble and insoluble assays
Samples were lysed in PBS containing 1% Triton X-100
and phosphatase/protease inhibitors on ice for 30 min.
After centrifugation at 15,000 g for 30 min at 4 °C,
Triton X-100 insoluble fractions were collected. Pellets
were washed 4x in lysis buffer. Pellets were further solu-
bilized in PBS containing 1% SDS, 1% Triton X-100, and
phosphatase/protease inhibitors at 60 °C for 1 h. Triton
X-100 insoluble fractions were collected after centrifuga-
tion at 15,000 g for 30 min at 4 °C. A BCA assay was
done on the lysates to ensure equal protein concentra-
tions for western blot. This procedure was described
elsewhere [14].
Fluorescence microscopy
Mice were transcardially perfused with ice cold PBS to
remove excess blood, then perfused with cold 4% pa-
raformaldehyde. Brain sections were blocked in PBS
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containing 3% BSA and 0.1% Triton X-100 for 1 h at
room temperature. Sections were then incubated with
primary antibodies in blocking buffer overnight at 4 °C.
After washing 3 times in PBS sections were incubated
with Alexa-conjugated secondary antibody for 1 h at
room temperature. Secondary antibody was goat anti-
mouse Alexa Fluor 555. After 3 more washes with PBS,
sections were mounted with mounting medium (Pro-
Long Gold antifade mountant with DAPI, Invitrogen).
Cells were examined under Carl Zeiss upright or invert
confocal microscopes (LSM780 system). Images were
taken with 63X oil immersion objective lens at room
temperature and image acquisition was performed by
Zen2012 software.
Animals
All animal studies were performed in compliance with
IACUC (Institutional Animal Care and Use Committee)
at Icahn School of Medicine at Mount Sinai. Heterozygous
z_Q175 and littermate controls were obtained from the
CHDI colony at the Jackson Laboratories. For imaging
analysis, GFP-LC3 expressing mice [18] were crossed with
z_Q175 mice. All mice used were aged 12–15 months.
Statistical analysis
Data are presented as mean ± SEM from at least three
independent experiments. Statistical analysis was per-
formed with GraphPad Prism v5.0 (Graphpad Software).
For data normalized with control group (a value of 1),
one sample t-tests against a hypothetical value of 1 were
used to compare the difference between the other group
and control group. For other non-normalized values,
unpaired Student’s t-tests were used. For multifactorial
analysis, a two-way ANOVA was used. Bonferroni’s
correction was used for multiple comparisons. P values
<0.05 were considered as statistically significant.
Results
ULK1 phosphorylates ATG14 at serine 29
Previous reports raise the possibility that ULK1 directly reg-
ulates ATG14 to influence autophagy [6, 12]. Recent studies
have identified a conserved ULK1 phosphorylation consen-
sus sequence [19, 20]. ATG14 contains a similar motif,
LXXSVD, at serine 29 (Fig. 1a). Following overexpression
of ULK1 and ATG14 in HEK293 cells, we observed that
ULK1 wildtype was able to co-immunoprecipitate with
ATG14, whereas the interaction of a mutant ULK1, kinase-
inhibited (KI) was decreased (Fig. 1b). To examine if ULK1
phosphorylates ATG14 at S29, we performed an in vitro
kinase assay in which we incubated myc-ULK1 protein and
a purified ATG14 fragment (amino acids 20–73) together
in the presence of 32P labeled ATP. The ATG14 fragment
showed incorporation of 32P when incubated with ULK1
WT but not with mutant KI (Fig. 1c). In contrast, the S29
alanine mutant fragment showed no incorporation of 32P.
We also included S61A as a control in the assay, and the
Fig. 1 ULK1 phosphorylates ATG14 at serine 29. a Representation of ATG14 structure with the location of serine 29. 4C-ER – cysteine repeats
needed for ER localization. CCD – coiled-coil domains. BATS – BARKOR autophagosome targeting sequence. b Co-immunoprecipitation of ATG14
and ULK1. Myc-ULK1 and ATG14-GFP were overexpressed in HEK cells and pulled down using antibodies against GFP. c Autoradiogram from
in-vitro kinase assay with ULK1 and ATG14 a.a. 20–73. Myc-ULK1 WT, KI, or empty vector was overexpressed in HEK cells and immunopurified with
antibodies against myc. ATG14 a.a. 20–73 WT, S29A, or S61A were purified from e. coli. MBP (myelin basic protein) was used as a positive control.
d Similar experiment as (c), except using an antibody against phosphorylated serine 29. e ATG14-GFP and myc-ULK1 WT or KI were co-transfected in
HEK cells. Half of the IP was treated with an alkaline phosphatase at 37 °C for 30 min
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result showed no effect of the mutation on 32P labeling,
suggesting the specificity of S29 phosphorylation by ULK1
in-vitro.
We then developed an antibody against phosphory-
lated S29 of ATG14, which detected the purified ATG14
fragment in the presence of ULK1 WT but not ULK1 KI
mutant (Fig. 1d). In cultured cells, overexpression of
ULK1 WT, but not ULK1 KI, increased ATG14 phos-
phorylation, which is diminished after treatment with an
alkaline phosphatase for 30 min (Fig. 1e).
ATG14 phosphorylation at Ser29 by ULK1 is regulated by
the mTOR pathway
We next determined if ATG14 S29 phosphorylation
occurs upon autophagy induction. Treatment with Torin
1, a potent mTOR inhibitor [21], caused robust phosphor-
ylation of S29 of ATG14 in HCT116 cells. In addition,
amino acid starvation, serum removal, and culture
medium starvation all caused an increase in S29 phos-
phorylation (Fig. 2a, b). Glucose withdrawal, however, did
not lead to phosphorylation of ATG14 despite the increase
in LC3-II (Additional file 1a), possibly because ULK1/2
-mediated ATG14 phosphorylation is required for amino
acid starvation - induced autophagy, but not for glucose
withdrawal [22]. Furthermore, a time course analysis
showed that ATG14 is phosphorylated as early as 15 min
after Torin 1 treatment and appeared to reach a steady
state shortly thereafter (Fig. 2c, d). The same effect was
seen total medium starvation with Hank’s Balanced Salt
Solution (HBSS), albeit at a slightly slower rate (Additional
file 1b, c).
ULK1-mediated Beclin 1 phosphorylation is promoted
by the presence of ATG14 [23]. To assess the require-
ment of Beclin 1 in ATG14 phosphorylation, we treated
Beclin 1 KO MEF cells with Torin 1 and then examined
ATG14 pS29 levels. The result showed that the ability of
Fig. 2 ATG14 is phosphorylated in an mTOR-dependent fashion by ULK1 upon autophagy induction. a Phosphorylation of ATG14 in HCT116 cells
after glucose, serum, or amino acid withdrawal, medium starvation with HBSS, or Torin 1 treatment for 6 h. b ATG14 phosphorylation levels were
normalized to total ATG14 levels and compared to the control condition. **p < 0.01 *p < 0.05 n.s. not significant (n = 3). Data are represented as
mean +/− SEM. c ATG14 phosphorylation after 15, 30, 60, and 120 min of Torin 1 treatment in HCT116 cells. d ATG14 phosphorylation levels were
normalized to total ATG14 levels and compared to the control condition. A one-way ANOVA with Bonferroni’s posttest was performed. F(4, 10) = 12.58,
p = 0.0006 ***p < 0.001 **p < 0.01 *p < 0.05 (n = 3). Data are represented as mean +/− SEM. e ATG14 phosphorylation in Beclin WT, KO or Beclin rescued
MEF cells treated with Torin 1 or vehicle (DMSO) for 60 min. Arrow indicates pATG14 band. f Quantification of ATG14 phosphorylation normalized to
total ATG14. **p < 0.01 (n = 3). Data are represented as mean +/− SEM. g MEF WT and ULK1/2 DKO cells were treated with Torin 1 for 60 min. ATG14
was immunopurified to enhance the phospho-signal. h Validation of phospho-ATG14 (S29) antibody specificity. ATG14 phosphorylation
signal disappears in ATG14 KO HCT116 cells after medium starvation or Torin 1 treatment for 60 min
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ULK1 to phosphorylate ATG14 S29 is severely impaired
in Beclin 1 KO MEF cells, but that ATG14 pS29 levels
recover when an exogenous Beclin 1 is reintroduced
(Fig. 2e, f ).
To test the specific role for ULK1/2 kinases in phos-
phorylating ATG14, we treated ULK1/2 double knock-
out (DKO) MEF cells with Torin 1. Torin 1-induced
ATG14 phosphorylation was detected in wildtype MEF
cells but not in ULK1/2 DKO MEF cells (Fig. 2g).
Knocking out ATG14 completely abolished the phos-
phorylation signal after Torin 1 and HBSS incubation,
indicating the specificity of the anti-pS29 ATG14
antibody (Fig. 2h). Thus our results demonstrate that
ULK1-mediated phosphorylation of ATG14 S29 is
regulated by the mTOR pathway.
Phosphorylation of ATG14 S29 critically regulates Vps34
lipid kinase activity
To examine the role for pS29 of ATG14 in Vps34 kinase
activity, we generated ATG14 phosphorylation mutants
either to mimic phosphorylation (S/E) or suppress phos-
phorylation (S/A). FLAG-ATG14 S29E-associated Vps34
showed a significant increase in lipid kinase activity
compared to that of FLAG-ATG14 S29A (Fig. 3a, b).
Fig. 3 ATG14 phosphorylation promotes Vps34 lipid kinase activity. a Vps34 lipid kinase assay. Empty vector or FLAG-ATG14 S29 WT, A, or E mutants
were overexpressed in HEK cells and pulled down using antibodies against FLAG. b Quantification of PI(3)P levels were normalized to levels of Vps34
in the IP. Values were then normalized to the WT condition. **p < 0.01 (n = 5). Data are represented as mean +/− SEM. c Co-immunoprecipitation of
ATG14 and Vps34 complex members, Beclin 1, Vps34, Vps15 and NRBF2. Empty vector or FLAG-ATG14 S29 WT, A, or E mutants were overexpressed in
HEK cells and pulled down using antibodies against FLAG. d Torin 1 treatment does not alter binding of Vps34 complex members. MEF cells were
treated with Torin 1 for 60 min. Cell lysates were subject to IP using antibody against ATG14. e Phosphorylation levels of Beclin 1 and ATG14 from
HCT116 cells treated with Torin 1 for 15, 30, 60, and 120 min. f Vps34 lipid kinase assay for Beclin 1 and ATG14 phosphorylation mutation comparison.
Beclin 1-AsRed, FLAG-ATG14, and dual myc-Vps34 his-Vps15 plasmid were overexpressed and purified from HEK cells using antibodies against FLAG. g
Quantification of PI(3)P levels were normalized to levels of Vps34 in the IP. Values were then normalized to the WT condition. Two-way ANOVA analysis
with Bonferroni posttest was used for the effect of the nature of the mutation and which protein was being mutated. Main effect of Beclin 1 or ATG14
mutation F(1, 18) = 4.08, p = 0.0587; Main effect of type of mutation F(1, 18) = 0.71, p = 0.5043; Interaction F(2, 18) = 3.80, p = 0.0421. **p < 0.01 (n = 5).
Data are represented as mean +/− SEM
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Previous studies identified multiple protein components
in Vps34 autophagy complex [11, 24, 25]. To test
whether ATG14 pS29 interferes with the interaction of
ATG14 and the other components, thus affecting Vps34
activity, we performed co-immunoprecipitation experi-
ments from cells transfected with FLAG-tagged ATG14
variants. In examining the endogenous ATG14 binding
proteins through FLAG pull-down, we detected no
changes in the levels of Beclin 1, NRBF2, Vps15, or
Vps34, comparing wildtype ATG14 to S29E or S29A
mutants (Fig. 3c). Furthermore, treatment with Torin 1
had no effect on Beclin 1, Vps34, or NRBF2 binding to
ATG14 (Fig. 3d). Thus the increased Vps34 activity
caused by ATG14 pS29 is unlikely due to the change of
ATG14 interactions with above components in the
Vps34 complex.
Recent structural analysis of the Vps34 complex re-
veals that the N-termini of ATG14 and Beclin 1 are in
close proximity [26, 27]. Beclin 1 is necessary for ATG14
phosphorylation and stabilization (Fig. 2e, [9]) and
ATG14 is necassary for Beclin 1 phosphorylation [23].
Given the tight association of ATG14 and Beclin 1 pro-
teins, we investigated the relationship between ATG14
and Beclin 1 phosphorylation. We found that ATG14
and Beclin 1 are phosphorylated following the same
trend upon Torin 1 treatment (Fig. 3e). To distinguish
the individual contributions of Beclin 1 and ATG14
phosphorylation to Vps34 activity regulation, we exam-
ined Vps34 activity in the presence of various combina-
tions of ATG14 and Beclin 1 phosphorylation variants.
FLAG-ATG14 WT, S29A, and S29E were co-expressed
with Beclin 1-AsRed S14A and Vps34 was pulled down
using antibodies against FLAG. Similarly, Beclin 1-
AsRed WT, S14A, and S14E were co-expressed with
FLAG-ATG14 S29A. Interestingly, ATG14 S29E is able
to increase Vps34 activity despite the presence of Beclin
1 S14A. In contrast, Beclin 1 S14E is unable to enhance
Vps34 activity in the presence of ATG14 S29A (Fig. 3f, g).
Thus our result suggests that ULK1-mediated ATG14
phosphorylation is critical to promoting Vps34 activity.
Mutant Huntingtin causes a reduction in ATG14
phosphorylation and ATG14-Vps34 kinase activity in HD
mouse brain
In an earlier study, we identified an ULK1-mediated
phosphorylation site on p62 [14]. During proteotoxic
stress induced by expression of mutant Htt, p62 phos-
phorylation is increased in cell and mouse models of
HD. We therefore sought to further dissect the autoph-
agy pathway in HD using ATG14 phosphorylation as an
autophagy measure. To do this, we used the Q175 mice,
an HD model carrying a knock-in allele of mutant
Huntingtin containing ~175 glutamine repeats [28].
Opposite to the reported increased p62 phosphorylation
levels, we found that Q175 mice displayed a ~40%
decrease in pS29 levels in the cortex, despite unchanged
total ATG14 protein levels (Fig. 4a, b). We then assessed
Vps34 activity, since ATG14 phosphorylation is suffi-
cient to regulate its lipid kinase activity (Fig. 3). We
pulled down ATG14-associated Vps34 complex from the
cortex of Q175 mice using antibodies against ATG14.
As expected, we found that ATG14-associated Vps34 ac-
tivity was decreased in Q175 brain (Fig. 4c, d). We also
examined the Beclin 1 phosphorylation, an ULK1 kinase
substrate that was implicated in regulating Vps34 activ-
ity [23]. Western blot analysis showed a reduced level of
Beclin 1 phoshp-Ser14 in Q175 brains compared to
control mice (Fig. 4e, f ). Thus our results suggest a de-
crease in ULK1-mediated regulation of ATG14-associated
Vps34 kinase activity in Q175 brains.
We also examined ATG14 phosphorylation an HD cell
model, which expresses the N-terminus of Htt following
103 polyQ repeats [13]. Cells expressing mCFP-103Q
fragments also showed a decrease in ATG14 phosphoryl-
ation (Fig. 4g, h).
To understand autophagic activity in HD, we exam-
ined autophagosome formation in the Q175 mice, which
expressed green fluorescence protein fused with LC3
(GFP-LC3) as reporter [18] after crossing GFP-LC3 mice
to Q175 mice. Despite the expression of mutant polyQ-
Htt protein, which accumulates into nuclear aggregates,
there was little change in GFP-LC3 fluorescence inten-
sity or distribution in 6, 10 or 15 month old mice, indi-
cating no obvious change in autophagosome formation
or block of autophagosome clearance (Fig. 4i). The
observation is in contrast to the Lurcher mice, where
mutant Purkinje cells produce a large number of GFP-
LC3 associated autophagosomes prior to degeneration in
response to excitotoxic stimuli [29]. They also differ
from HdhQ200 mice (Knock-in), which are related to
Q175 mice and display accumulation of perinuclear
mHtt aggregates accompanied by the increase in autop-
hagsome markers LC3 II and p62 protein levels [3]. Ana-
lysis of LC3II in Q175 brain, however, shows no obvious
change of its protein levels compared to wildtype brain
(Additional file 2 a, b). Together with the previous data
indicating little change in p62 total levels in Q175 brain
[14], the results therefore suggest no significant impair-
ment of autophagic activity in the brain of Q175 mice.
Thus the ~35% decrease of ATG14-linked Vps34 activity
(Fig. 4c, d) does not corroborate a significance reduction
of basal autophagy in the Q175 brain.
Proteotoxic stress causes a reduction in ATG14
phosphorylation and redistribution of ULK1 to an
insoluble cellular fraction
Proteotoxic stress induced by proteasomal inhibition
also promotes ULK1-mediated phosphorylation of p62/
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SQSTM1, an autophagy receptor in selective autophagy
[14]. To understand the impact of proteotoxic stress on
ATG14 phosphorylation, we treated MEF cells with
MG132, a proteosomal inhibitor. Similar to the effect of
mutant Htt expression, MG132 caused a marked de-
crease in ATG14 p-S29 (Fig. 5a, b). As expected, p62
Fig. 4 ATG14-associated Vps34 activity is reduced in Q175 brains. a ATG14 phosphorylation in Q175 brains. ATG14 was immunopurified using
antibodies against ATG14. Two representative lanes shown for each experiment. b Quantification of ATG14 phosphorylation. **p < 0.01 (n = 5).
Data are represented as mean +/− SEM. c In-vitro lipid kinase assay of Vps34 complex pulled down with antibodies against ATG14 from the brains
of Q175 mice. Thin layer chromatography was used to separate 32P-PI(3)P. d Quantification of PI(3)P levels were normalized to levels of Vps34 in
the IP. ***p < 0.001 (n = 4). Data are represented as mean +/− SEM. e Beclin 1 S14 phosphorylation in Q175 mice. f Quantification of Beclin 1
phosphorylation. **p < 0.01 (n = 5). Data are represented as mean +/− SEM. g ATG14 phosphorylation in mCFP-103Q expressing HeLa cells.
Doxycycline was removed for 7 days to induce protein expression. IP was performed against ATG14. h Quantification of ATG14 phosphorylation. Values
were normalized to control. *p < 0.05 (n = 4). Data are represented as mean +/− SEM. I Immunofluorecent imaging of autophagosome reporter
GFP-LC3 distribution in striatal nuclei of Q175;GFP-LC3 and control WT;GFP-LC3 mice. Mice at 6, 10 and 15 months are examined. mHtt nuclear
aggregate staining in red and GFP-LC3 in green. Scale bar 10 μm
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accumulated in the insoluble fraction, but ATG14 did
not. Consistent with our previous results, there was also
a decrease in soluble ULK1 levels but an increase in
insoluble ULK1 levels (Fig. 5a; [14]). In Q175 mice, we
also see a similar accumulation of ULK1 in the insoluble
fraction (Fig. 5c, d), albeit to a lesser degree. This could
be a result of the difference between cell type homogen-
eity and mutant Htt expression in the Q175 brain.
Given that ULK1 phosphorylates both p62 and ATG14,
it is surprising that these signaling events appear to be
differentially regulated. Moreover, we showed previously
that p62-ULK1 binding is increased in the presence of
mutant Htt or proteotoxic stress [14]. We therefore
hypothesize that the differential regulation can be, in part,
explained by p62 competing with ATG14 (both as sub-
strates) for ULK1 kinase activity. To test this hypothesis,
we examined pS29 ATG14 levels in wildtype and p62 KO
MEF cells after MG132 treatment. We observed higher
levels of ATG14 phosphorylation in p62-depleted cells
treated with MG132 when compared to WT (Fig. 5e, f ).
Interestingly, we also notice less ULK1 in the insoluble
fraction in p62 KO MEF compared to control cells
(Fig. 5g), consistent with the loss of p62 competition or
sequestration, which would otherwise recruit ULK1 into
the insoluble fraction.
ATG13 and FIP200 are components of ULK1 com-
plex and important for ULK1 kinase regulation. We
then tested whether MG132 can alter the binding of
ATG13 and FIP200 with ULK1 and localization of
ATG13 and FIP200, which may account for the de-
crease of ATG14 phosphorylation. We found that
MG132 treatment does not alter the interaction be-
tween ULK1 and ATG13 or FIP200 as assayed by co-IP;
however, MG132 treatment causes FIP200 and ATG13
redistribution into insoluble fraction (Additional file 3
a, b). Thus the result suggests that p62 sequestration of
ULK1-ATG13-FIP200 complex into insoluble fraction
leads to reduced ATG14 phosphorylation.
ULK1-mediated ATG14 phosphorylation promotes
disease-related polyQ protein degradation
Previous evidence indicated a role for Vps34 activity in HD:
blocking Vps34 activity increases the levels of polyQ pro-
tein [30, 31], while addition of synthetic PI(3)P, the Vps34
product, aids in the clearance of polyQ protein [13]. Given
the role of autophagy in the clearance of protein aggregates,
Fig. 5 Proteotoxic stress causes a decrease in ATG14 phosphorylation and a redistribution of ULK1 into insoluble fraction. a ATG14 phosphorylation
after proteasome inhibition. Phosphorylation of p62 is at S409. MEF cells were treated with MG132 for 16 h then separated into Triton X-100 soluble
and insoluble fractions. b Quantification of ATG14 phosphorylation. ***p < 0.001 (n = 3). Data are represented as mean +/− SEM. c ULK1 accumulates in
the Triton X-100 insoluble fraction in the brains of Q175 mice. d Quantification of ULK1 in the insoluble fraction. *p < 0.05 (n = 3). Data are represented
as mean +/− SEM. e ATG14 phosphorylation after proteasome inhibition. P62 WT or KO MEF cells were treated with MG132 for 16 h then separated
into Triton X-100 soluble and insoluble fractions. f Quantification of ATG14 phosphorylation in the soluble fraction. Two-way ANOVA was performed.
Main effect of MG132 F(1, 8) = 92.60, p < 0.0001; Main effect of p62 KO F(1, 8) = 0.56, p = 0.4748; Interaction F(1, 8) = 7.82, p = 0.0233. (n = 3). Data are
represented as mean +/− SEM. g Quantification of ULK1 in the insoluble fraction. Main effect of MG132 F(1, 8) = 252.94, p < 0.0001; Main effect of p62
KO F(1, 8) = 87.94, p < 0.0001; Interaction F(1, 8) = 81.33, p < 0.0001 (n = 3). Data are represented as mean +/− SEM
Wold et al. Molecular Neurodegeneration  (2016) 11:76 Page 9 of 13
we next asked if pS29 ATG14 facilitates the removal of
polyQ proteins. We overexpressed the ATG14 variants
along with other Vps34 complex components in mCFP-
65Q expressing HeLa cells as we described in our earlier
study [14]. The result shows increased degradation of insol-
uble mCFP-65Q in the presence of S29E ATG14, compared
to S29A, supporting the idea that ATG14 pS29 promotes
the degradation of polyQ mutant (Fig. 6a, b).
Because our data showed that reducing p62 levels par-
tially restores ATG14 phosphorylation, we hypothesized
that ULK1 is a limiting factor in autophagic clearance of
polyQ protein. We therefore asked if an increase in over-
all ULK1 kinase level could provide a beneficial role for
the autophagic clearance of mutant Htt. To this end, we
overexpressed the WT or KI mutant of ULK1 in mCFP-
65Q cells. We found that overexpression of ULK1 WT
but not ULK1 KI was able to effectively reduce insoluble
mCFP-65Q protein levels (Fig. 6c, d). Taken together,
our result provides evidence for ULK1-mediated ATG14
phosphorylation as a potential drug target for HD by en-
hancing autophagic clearance of mutant Htt aggregates.
Discussion
Autophagy modulation is being pursued as a therapeutic
strategy for neurodegenerative diseases associated with
protein aggregates. Thus, a better understanding of the
autophagy status in the disease process is critical to this
endeavor. Our study provides an insight into the mech-
anism of autophagy regulation whereby ULK1/2 signals
to autophagy-specific Vps34 complex to activate autoph-
agy through the mTOR nutrient pathway. We find that
ULK1 mediates ATG14 phosphorylation at a novel serine
site, S29, in response to amino acid (but not glucose) star-
vation, which in turn up-regulates Vps34 kinase activity.
Importantly, we find that the specific ATG14 phosphoryl-
ation and ATG14-associated VSP34 activity, which is
autophagy-specific, are impaired in HD cell and animal
models. Interestingly, our current assays suggest no ob-
vious impairment of autophagic activity in the brain of
Q175 mice. Thus the 35% decrease of ATG14-linked
Vps34 activity does not corroborate a significance reduc-
tion of basal autophagy in the HD animal models. Note
that our autophagy assays are based on GFP-LC3 reporter
Fig. 6 ULK1 activity regulates the degradation of polyQ proteins. a FLAG-ATG14 S29 WT, SA, or SE, Beclin 1-AsRed, and dual myc-Vps34 his-Vps15
plasmid were overexpressed in mCFP-65Q expressing HeLa cells then treated with rapamycin overnight. Cell lysates were separated into soluble
and insoluble fractions. PolyQ was measured in the insoluble fraction. b Quantification of polyQ degradation in the insoluble fraction. Degradation
was calculated as the ratio of control sample vs. rapamycin sample **p < 0.01 (n = 4). Data are represented as mean +/− SEM. c Myc empty vector,
myc-ULK1 WT or KI were overexpressed in mCFP-65Q expressing HeLa cells and cells were lysed 48 h after transfection. Cell lysates were separated into
soluble and insoluble fractions. PolyQ was measured in the insoluble fraction. d Quantification of polyQ levels in the insoluble fraction. Values were
normalized to empty vector condition. *p < 0.05 n.s. not significant (n = 4). Data are represented as mean +/− SEM
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and protein levels of several autophagy markers including
p62 [14], LC3II, ULK1, and Beclin 1-VPS34-ATG14 pro-
tein levels; they are limited in that they do not reflect
accurately the autophagy flux, which has been extremely
challenging to study in vivo. It is possible that transient,
subtle and regional changes of autophagy in Q175 mice
are difficult to detect using available approaches with low
sensitivity. We thus postulate that monitoring ATG14
phosphorylation and ATG14-Vps34 activity provides a
new means for in-vivo autophagy pathway analysis
which serves as a useful biomarker for altered au-
tophagy signaling in disease.
Interestingly, a previous study in HdhQ200 knockin
model, which manifests an accelerated and robust phe-
notypes than Q175 mice, has perinulear mHtt foci
accompanied by colocalized LC3 and p62 aggregates.
The HdhQ200 mice have increased levels of LC3II and
p62 levels in the striatal neurons [3]. Although inter-
preted as the induction of autophagy, the available
evidence indeed informs little regarding the exact direc-
tion change of autophagy or autophagy flux, nonetheless
shows the alteration of autophagy in HdhQ200 mice. Our
study found no perinuclear mHtt in Q175 HD brain, which
may explain the lack of GPF-LC3 puncta formation. The
lack of GFP-LC3 puncta in control GFP-LC3 mice is con-
sistent with the idea that basal autophagosome formation is
extremely rare in wildtype neurons as described by Mizush-
ima’s group [3]. Then it is not surprising that no GFP-LC3
puncta formation was found in Q175 neurons, as the re-
duced ATG14 phosphorylation and Vps34 activity as
shown in our study predicts even lower rate for autophago-
some formation. It is likely that accelerated accumulation
of mHtt aggregates in HdhQ200 mice causes apparent
change in LC3 and p62 levels. It would be interesting to in-
vestigate the ULK1-mediated ATG14 and Beclin 1 phos-
phorylation in HdhQ200 mice. Furthermore, future study
should examine whether a long term impact (e.g.
>15 months) of the decrease of ATG14-linked Vps34 activ-
ity can result in detectable reduction of autophagy mea-
sured through autophagic markers such as LC3 and p62.
ULK1-mediated phosphorylation of ATG14 may repre-
sent an important signaling event for autophagy in-
duction that coordinates the action of the two key
components of autophagy machinery, the ULK1 kinase
complex and ATG14-Vps34 complex (autophagy spe-
cific). During the preparation of this manuscript, Park,
et al. published their independent discovery of ATG14
phosphorylation by ULK1 [32]. Their results are in an
agreement with our conclusion that Vps34 activity is regu-
lated by ATG14 phosphorylation and demonstrate its
positive effects on autophagosome formation. A previous
study showed that ULK1-mediated Beclin 1 phosphoryl-
ation contributes to the regulation of Vps34 activity [23].
However, it showed that ULK1-mediated Beclin 1
phosphorylation is also promoted by both UVRAG and
ATG14. However, two separate reports reveal that
starvation-induced mTOR inhibition either has no effect
on UVRAG-Vps34 activity or decreases it by 60% [33, 34],
raising a question about the precise role for phosphoryl-
ation of Beclin 1 in upregulating Vps34 activity. Our
current data shows that, although phosphorylation of
ATG14 and Beclin 1 occur with the similar kinetics in
response to mTOR inhibition, ATG14 phosphorylation
status is able to regulate Vps34 activity independent of
Beclin 1 phosphorylation. Although it goes beyond the
scope of the present study, further clarification of the role
of Beclin 1 phosphorylation for UVRAG-Vps34 activ-
ity is warranted. Finally, given ATG14’s role at the
ER-mitochondria contact site (MAM) and the require-
ment of ULK1 in ATG14 puncta formation during
autophagy induction, it is possible that ULK1 activity
is involved in the recruitment of one or more Vps34
complex members to the MAM [12, 35].
Our detailed study of ULK1 kinase and ATG14-Vps34
lipid kinase show reduced activity of both kinases, sug-
gesting altered regulation of the autophagy pathway in
HD models. Both phosphorylated Beclin 1 and ATG14
levels are decreased in HD brains, indicating the lower
ULK1 kinase activity, which is regulated by mTOR nu-
trient pathway. The reduced ULK1-mediated ATG14 or
Beclin 1 phosphorylation was initially surprising, given
that ULK1-mediated p62 phosphorylation (mTOR-inde-
pendent) increases in the same models of HD [14].
Interestingly, this differential ULK1 activity (mTOR vs.
non-mTOR regulated) was also seen in cultured cells
following proteasomal stress. It is possible that the regu-
latory mechanism for the aberrant ULK1 activity is
shared between proteasomal stress and HD. Our data
suggests that autophagy receptor p62 plays a role in
regulating ULK1-mediated ATG14 phosphorylation upon
proteotoxic stress. From our earlier study, in both HD
(expressing polyQ-protein) and proteasomal stress condi-
tions, there is an increased binding between p62 and
ULK1, concurrent with competition of ULK1 by p62
oligomerization [14]. As a potential result, the access of
ATG14-Vps34 complex to ULK1 kinase may be reduced.
Our result also indicates proteasomal stress condition
causes sequestration of the whole ULK1-ATG13-FIP200
complex. A similar competition model for ULK1 binding
was also proposed by another group, in which Htt was
shown to pull ULK1 away from the inhibitory effects of
mTOR during selective autophagy [36]. Alternatively,
optineurin, another autophagy receptor, is involved in
aggrephagy and has also been shown to interact with Htt
and co-localize with ULK1 [37–40]. Therefore, we are
unable to rule out the possibility that other autophagy
receptors may also sequester ULK1 away from ATG14
during proteotoxic stress.
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Finally, our current work extends our previous report
that ULK1-mediated p62 phosphorylation in selective
autophagy helps clear polyQ protein [14] by showing that
ATG14 phosphorylation and ULK1 activity per se has
beneficial effects in the clearance of mutant Htt. By target-
ing ULK1 activity to regulate autophagy, the unintended
consequences of general mTOR inhibition can be avoided.
Future work should be aimed at exploring the modulation
of ULK1 activity for the treatment of neurodegenerative
diseases associated with protein aggregates.
Conclusions
As the major pathway for protein aggregate clearance,
autophagy has been heavily implicated in the HD patho-
genesis and considered a therapeutic target. However,
the exact molecular mechanisms at work remain elusive.
In this work, we identify a critical process during autop-
hagosome biogenesis that is disregulated following mu-
tant Htt-induced proteotoxic stress. We find that in the
canonical autophagy pathway, ULK1 phosphorylates
ATG14, which promotes Vps34 lipid kinase activity.
ATG14 phosphorylation and Vps34 activity, however,
are impaired in HD models. Our study highlights ULK1
and Vps34 as potential targets for the treatment of HD.
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